182 related articles for article (PubMed ID: 27180268)
1. Synergistic effect of pacritinib with erlotinib on JAK2-mediated resistance in epidermal gowth factor receptor mutation-positive non-small cell lung Cancer.
Ochi N; Isozaki H; Takeyama M; Singer JW; Yamane H; Honda Y; Kiura K; Takigawa N
Exp Cell Res; 2016 Jun; 344(2):194-200. PubMed ID: 27180268
[TBL] [Abstract][Full Text] [Related]
2. JAK2-related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor-activating mutation.
Harada D; Takigawa N; Ochi N; Ninomiya T; Yasugi M; Kubo T; Takeda H; Ichihara E; Ohashi K; Takata S; Tanimoto M; Kiura K
Cancer Sci; 2012 Oct; 103(10):1795-802. PubMed ID: 22712764
[TBL] [Abstract][Full Text] [Related]
3. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
Nakagawa T; Takeuchi S; Yamada T; Nanjo S; Ishikawa D; Sano T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Sekido Y; Uenaka T; Yano S
Mol Cancer Ther; 2012 Oct; 11(10):2149-57. PubMed ID: 22844075
[TBL] [Abstract][Full Text] [Related]
4. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
Wang Y; Singh R; Wang L; Nilsson M; Goonatilake R; Tong P; Li L; Giri U; Villalobos P; Mino B; Rodriguez-Canales J; Wistuba I; Wang J; Heymach JV; Johnson FM
Oncotarget; 2016 Jul; 7(30):47998-48010. PubMed ID: 27384992
[TBL] [Abstract][Full Text] [Related]
5. Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer.
Tong X; Tanino R; Sun R; Tsubata Y; Okimoto T; Takechi M; Isobe T
Respir Res; 2019 Dec; 20(1):270. PubMed ID: 31791326
[TBL] [Abstract][Full Text] [Related]
6. MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells.
Presutti D; Santini S; Cardinali B; Papoff G; Lalli C; Samperna S; Fustaino V; Giannini G; Ruberti G
PLoS One; 2015; 10(11):e0143333. PubMed ID: 26580964
[TBL] [Abstract][Full Text] [Related]
7. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.
Donev IS; Wang W; Yamada T; Li Q; Takeuchi S; Matsumoto K; Yamori T; Nishioka Y; Sone S; Yano S
Clin Cancer Res; 2011 Apr; 17(8):2260-9. PubMed ID: 21220474
[TBL] [Abstract][Full Text] [Related]
8. Nicotine induces resistance to erlotinib via cross-talk between α 1 nAChR and EGFR in the non-small cell lung cancer xenograft model.
Li H; Wang S; Takayama K; Harada T; Okamoto I; Iwama E; Fujii A; Ota K; Hidaka N; Kawano Y; Nakanishi Y
Lung Cancer; 2015 Apr; 88(1):1-8. PubMed ID: 25670150
[TBL] [Abstract][Full Text] [Related]
9. JAK2 inhibitor TG101348 overcomes erlotinib-resistance in non-small cell lung carcinoma cells with mutated EGF receptor.
Zhang FQ; Yang WT; Duan SZ; Xia YC; Zhu RY; Chen YB
Oncotarget; 2015 Jun; 6(16):14329-43. PubMed ID: 25869210
[TBL] [Abstract][Full Text] [Related]
10. Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.
Howe GA; Xiao B; Zhao H; Al-Zahrani KN; Hasim MS; Villeneuve J; Sekhon HS; Goss GD; Sabourin LA; Dimitroulakos J; Addison CL
PLoS One; 2016; 11(3):e0150567. PubMed ID: 26962872
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of histone deacetylases sensitizes EGF receptor-TK inhibitor-resistant non-small-cell lung cancer cells to erlotinib in vitro and in vivo.
Yu W; Lu W; Chen G; Cheng F; Su H; Chen Y; Liu M; Pang X
Br J Pharmacol; 2017 Oct; 174(20):3608-3622. PubMed ID: 28749535
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of pyruvate dehydrogenase kinase 1 enhances the anti-cancer effect of EGFR tyrosine kinase inhibitors in non-small cell lung cancer.
Yang Z; Zhang SL; Hu X; Tam KY
Eur J Pharmacol; 2018 Nov; 838():41-52. PubMed ID: 30213498
[TBL] [Abstract][Full Text] [Related]
13. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.
Sette G; Salvati V; Mottolese M; Visca P; Gallo E; Fecchi K; Pilozzi E; Duranti E; Policicchio E; Tartaglia M; Milella M; De Maria R; Eramo A
Cell Death Dis; 2015 Aug; 6(8):e1850. PubMed ID: 26247735
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of Resistance and Novel Targets Mediating Resistance to EGFR and c-Met Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.
Botting GM; Rastogi I; Chhabra G; Nlend M; Puri N
PLoS One; 2015; 10(8):e0136155. PubMed ID: 26301867
[TBL] [Abstract][Full Text] [Related]
15. Curcumin lowers erlotinib resistance in non-small cell lung carcinoma cells with mutated EGF receptor.
Li S; Liu Z; Zhu F; Fan X; Wu X; Zhao H; Jiang L
Oncol Res; 2013; 21(3):137-44. PubMed ID: 24512728
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model.
Masuda C; Yanagisawa M; Yorozu K; Kurasawa M; Furugaki K; Ishikura N; Iwai T; Sugimoto M; Yamamoto K
Int J Oncol; 2017 Aug; 51(2):425-434. PubMed ID: 28627678
[TBL] [Abstract][Full Text] [Related]
17. Combined treatment with erlotinib and a transforming growth factor-β type I receptor inhibitor effectively suppresses the enhanced motility of erlotinib-resistant non-small-cell lung cancer cells.
Serizawa M; Takahashi T; Yamamoto N; Koh Y
J Thorac Oncol; 2013 Mar; 8(3):259-69. PubMed ID: 23334091
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation.
Santoni-Rugiu E; Grauslund M; Melchior LC; Costa JC; Sørensen JB; Urbanska EM
Lung Cancer; 2017 Nov; 113():14-17. PubMed ID: 29110841
[TBL] [Abstract][Full Text] [Related]
19. The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.
Nakachi I; Naoki K; Soejima K; Kawada I; Watanabe H; Yasuda H; Nakayama S; Yoda S; Satomi R; Ikemura S; Terai H; Sato T; Ishizaka A
Mol Cancer Res; 2010 Aug; 8(8):1142-51. PubMed ID: 20647329
[TBL] [Abstract][Full Text] [Related]
20. The novel phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor.
Sano T; Takeuchi S; Nakagawa T; Ishikawa D; Nanjo S; Yamada T; Nakamura T; Matsumoto K; Yano S
Int J Cancer; 2013 Jul; 133(2):505-13. PubMed ID: 23319394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]